Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The ...

Dr. Reddy's Laboratories Ltd. 500124 shares slid 5.01% to 1,224.70 Indian rupees Friday, on what proved to be an all-around ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...

Indian shares inched higher on Friday, tracking Asian peers after U.S. President Donald Trump said he would push for lower interest rates, while worries over moderation in domestic earnings capped ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Thursday reported profit of $167.3 million in its fiscal third quarter. The Hyderabad, India-based company said ...

Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, weighed down by pricing pressure in the competitive North American market, their biggest ...

Dr Reddy's Laboratories posted a 2% rise in net profit for Q3 2024, reaching Rs 1,413 crore, driven by strong market ...